Insulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system.
Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release.
Acton, Mass.–based Insulet said the device, which has FDA breakthrough device designation, significantly improved time in range and reduced Hba1c in children, adolescents and adults between age six and 70 with Type 1 diabetes. Insulet expects to launch the device in a limited release in the first half of this year.
Get the full story at our sister site, Drug Delivery Business News.
